2026 On-Site Exhibition Strategy: Bringing Our Expertise Closer to the Global Market
2026 On-Site Exhibition Strategy: Bringing Our Expertise Closer to the Global Market
As global industries continue to recover and evolve, face-to-face engagement remains one of the most effective ways to build trust and accelerate collaboration. In 2026, we will participate in a curated selection of international on-site exhibitions, strengthening our connection with global customers and partners through direct, solution-focused communication.
Why On-Site Exhibitions Still Matter in 2026
While digital communication plays an essential role in today’s business environment, on-site exhibitions remain irreplaceable—especially in highly technical and regulated industries. In-person discussions allow for deeper technical exchange, clearer value demonstration, and stronger relationship building.
Key Focus Areas for 2026
Targeted Markets and Purposeful Participation
In 2026, we will prioritize exhibitions closely aligned with our core products and application areas, including life sciences, pharmaceuticals, bioprocessing, and high-purity chemical applications. This focused approach ensures meaningful engagement with the right audiences.
Application-Driven Solutions
Rather than simply presenting product lists, our exhibition showcases emphasize real-world applications and practical solutions. We demonstrate how our products support process stability, quality consistency, and regulatory compliance across development and production.
Upcoming Exhibitions in 2026
| Exhibition | Booth / Meeting Location | Venue | Date |
|---|---|---|---|
| DCAT Week | Meeting Room: The Rink | 45 Rockefeller Plaza, New York, NY 10111, USA | March 24–25 |
| BioProcess International Europe | Booth 918 | Vienna, Austria | April 27–30 |
| CPHI Americas | Booth 1308 | USA | June 2–4 |
| BioProcess International Europe (Boston) | Booth 124 | Boston, USA | September 22–25 |
| CPHI Milan | Booth 1G34 | Milan, Italy | October 6–8 |
If you plan to attend any of these exhibitions, we welcome you to contact us in advance to schedule an on-site meeting with our team. We look forward to connecting with you and exploring potential collaboration opportunities.
ANDA MUNGKIN JUGA SUKA
-
News
Hopax Achieves A- Rating in the 2025 CDP Assessment, Demonstrating Strong Climate Leadership
2026.01.20
Hopax is proud to announce that we have achieved an A- rating in the 2025 Carbon Disclosure Project (CDP) assessment, marking a significant milestone in our sustainability journey.
-
News
A Greener Future for Life Sciences: Hopax Makes an Impact at CPHI Frankfurt
2025.11.19
Hopax presented its sustainability strategy at CPHI Frankfurt, highlighting EcoVadis Silver, SBTi targets, and IPEC-GMP certified bio-buffer production trusted by global life science partners. Watch our CPHI highlight reel for more.
-
Biopharmaceutical
MES Buffer: An Essential Component in Biological and Pharmaceutical
2025.02.21
MES is a biological buffer that is highly effective in maintaining a stable pH range between 5.5 and 7.0.
-
Biopharmaceutical
Evaluation of the Suitability of pH Buffers in Biological, Biochemical, and Environmental Studies
2024.08.02
Maintaining pH stability is crucial in biological, biochemical, and environmental research.
